Unique ID issued by UMIN | UMIN000022738 |
---|---|
Receipt number | R000026181 |
Scientific Title | Effects on the improvement of blood glucose and changes in body composition of oral anti-diabetic drug SGLT2 inhibitor.~ Relevance to the compliance of the diet therapy for diabetes~ |
Date of disclosure of the study information | 2016/06/14 |
Last modified on | 2018/02/02 09:41:35 |
Effects on the improvement of blood glucose and changes in body composition of oral anti-diabetic drug SGLT2 inhibitor.~ Relevance to the compliance of the diet therapy for diabetes~
Effect of SGLT2 inhibitor and diet therapy
Effects on the improvement of blood glucose and changes in body composition of oral anti-diabetic drug SGLT2 inhibitor.~ Relevance to the compliance of the diet therapy for diabetes~
Effect of SGLT2 inhibitor and diet therapy
Japan |
Diabetes
Endocrinology and Metabolism |
Others
NO
The SGLT2 inhibitor which is an oral medicine for diabetes exerts the blood glucose lowering effect by promoting urinary glucose excretion. The aim of this study is to clarify the effect of the improvement of blood glucose levels, the influence for the changing of body composition including body weight and muscle weight. In addition, we focus on the adherence to the diet therapy for diabetes, and determine the factors of the difference of the showing effect of SGLT2 inhibitor in the patients who show the effectiveness or non-effectiveness.
Safety,Efficacy
Amount of Parameters of blood glucose (HbA1c, fasting blood glucose, glycoalbumin, insulin,CPR)
1)Amount of change in Body weight
2)Amount of change in Body composition (fat, muscle etc.)
3)Carbohydrate intake
4)Urinary albumin excretion
5)eGFRcreat (calculation by conversion formula of GFRcreat in Japanese),
serum creatinine
6)Urinary L-FABP excretion, serum cystatinC (Cys-C), eGFRcys (calculation by conversion formula of eGFRcys in Japanese)
7)Serum lipid (T-cho, LDL, HDL, TG)
8)Blood pressure, pulse
9)Liver function(AST,ALT,gammaGTP)
10)Uric acid
11)Hematocrit
12)Ketone Body,Lactic acid
13)BDHQ: intake of energy, protein, lipid and dietary fiber, nutritional education
Observational
20 | years-old | <= |
80 | years-old | > |
Male and Female
Outpatients and hospitalized patients in the department of endocrinology and metabolism of Kanazawa Medical University Hospital.
The diabetic patiens who have the adaptation for the treatment of SGLT2 inhibitor that was judged by the physician (>=20 and<=80 of age)
None
30
1st name | |
Middle name | |
Last name | Daisuke Koya |
Kanazawa Medical University
Diabetology and Endocrinology
1-1Daigaku,Uchinada,Kahoku-gun, Ishikawa Prefecture, 920-0293
076-286-2211
koya0516@kanazawa-med.ac.jp
1st name | |
Middle name | |
Last name | Yuka Kuroshima |
Kanazawa Medical University
Diabetology and Endocrinology
1-1Daigaku,Uchinada,Kahoku-gun, Ishikawa Prefecture, 920-0293
076-286-2211
naipicrc@kanazawa-med.ac.jp
Kanazawa Medical University
None
Self funding
NO
2016 | Year | 06 | Month | 14 | Day |
Published
Completed
2015 | Year | 05 | Month | 20 | Day |
2015 | Year | 06 | Month | 02 | Day |
We clarify the effect of the improvement of blood glucose levels, the influence for the changing of body composition including body weight and muscle weight. In addition, we focus on the adherence to the diet therapy for diabetes, and determine the factors of the difference of the showing effect of SGLT2 inhibitor in the patients who show the effectiveness or non-effectiveness.
2016 | Year | 06 | Month | 14 | Day |
2018 | Year | 02 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026181
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |